cytarabine has been researched along with Minimal Disease, Residual in 146 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (11.64) | 18.2507 |
| 2000's | 41 (28.08) | 29.6817 |
| 2010's | 63 (43.15) | 24.3611 |
| 2020's | 25 (17.12) | 2.80 |
| Authors | Studies |
|---|---|
| Alakel, N; Bornhäuser, M; Chemnitz, J; Döhner, H; Döhner, K; Fransecky, L; Gaidzik, V; Germing, U; Götze, KS; Haas, R; Hänel, M; Hanoun, M; Henning, L; Heuser, M; Holderried, TAW; Holtick, U; Jehn, CF; Kaiser, U; Kobbe, G; Koch, K; Kraus, S; Krause, SW; Kriege, O; Krüger, W; Lauseker, M; Middeke, JM; Morgner, A; Neuerburg, C; Platzbecker, U; Rautenberg, C; Röhnert, MA; Röllig, C; Sauer, T; Schäfer-Eckart, K; Schetelig, J; Schliemann, C; Scholl, S; Schröder, J; Schroeder, T; Severmann, J; Sockel, K; Stelljes, M; Stölzel, F; Thol, F; Unglaub, JM; Verbeek, M; Vucinic, V; Wagner-Drouet, E; Wass, M | 1 |
| Aldrich, J; Alvarado, Y; Borthakur, G; Daver, N; DiNardo, C; Garcia-Manero, G; Kadia, T; Ohanian, M; Patel, K; Pemmaraju, N; Ravandi, F; Senapati, J; Shoukier, M; Wang, X | 1 |
| Ben Khoud, M; Brinster, C; Figeac, M; Leprêtre, F; Mopin, A; Quesnel, B; Sebda, S; Villenet, C | 1 |
| Elonen, E; Huhtala, H; Itälä-Remes, M; Jantunen, E; Kairisto, V; Kauppila, M; Koistinen, P; Koivunen, E; Kolonen, A; Kuittinen, T; Nousiainen, T; Ollikainen, H; Pelliniemi, TT; Penttilä, K; Porkka, K; Pyörälä, M; Räty, R; Rauhala, A; Rimpiläinen, J; Rintala, H; Ruutu, T; Säily, M; Sankelo, M; Silvennoinen, R; Sinisalo, M; Volin, L | 1 |
| Balsat, M; Barraco, F; Ducastelle-Leprêtre, S; Fossard, G; Ghesquières, H; Gilis, L; Hayette, S; Heiblig, M; Huet, S; Labussière-Wallet, H; Larcher, MV; Loron, S; Meur, GL; Michallet, M; Plesa, A; Renault, M; Sujobert, P; Thérèse, RM; Thomas, X; Tigaud, I | 1 |
| Chiba, S; Hattori, K; Kato, T; Kurita, N; Maruyama, Y; Nanmoku, T; Nishikii, H; Obara, N; Sakamoto, T; Sakata-Yanagimoto, M; Suehara, Y; Tsuboi, Y; Yokoyama, Y; Yoshida, C | 1 |
| Chang, WI; MacDonell-Yilmaz, RE; Moynihan, L; Sampino, EV; Sprinz, PG | 1 |
| Campana, D; Cheng, C; Coustan-Smith, E; Lins, MM; Lucena-Silva, N; Pedrosa, A; Pedrosa, F; Pedrosa, M; Ramos, AML; Ribeiro, RC; Rivera, GK; Vinhas, E; Zhou, Y | 1 |
| Biffi, A; Buffardi, S; Buldini, B; Carraro, E; Cavallaro, E; Cellini, M; D'Amore, ESG; Damanti, CC; Gallingani, I; Lovisa, F; Micalizzi, C; Mussolin, L; Piglione, M; Pillon, M; Sala, A; Santoro, N; Vinti, L | 1 |
| Gong, L; Huang, X; Jia, J; Jiang, H; Jiang, Q; Lai, Y; Liu, K; Liu, X; Lu, R; Lu, S; Ruan, G; Shi, H; Wang, J; Wang, Y; Wu, Y; Xu, L; Yan, C; Zhang, X; Zhao, X | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Baker, R; Burt, R; Farah, N; Ibrahim, AR; Kottaridis, PD | 1 |
| Banavali, S; Gujral, S; Myint, HH; Narula, G; Patkar, N; Prasad, M; Subramanian, P; Tandon, S; Tembhare, P | 1 |
| Candoni, A; Canichella, M; Cavalli, M; Chiaretti, S; Conter, V; D'Aloisio, M; De Propris, MS; Elia, L; Fazi, P; Foà, R; Guarini, A; Luppi, M; Martino, B; Messina, M; Moleti, ML; Piciocchi, A; Starza, ID; Testi, AM; Vignetti, M; Vitale, A | 1 |
| Ai, WZ; Andreadis, CB; Damon, L; Fakhri, B; Huang, CY; Hunter, B; Kambhampati, S; Kaplan, L; Martin, T; Pampaloni, M; Varnavski, A | 1 |
| Chen, HQ; Fang, JP; Li, CG; Li, CK; Li, JQ; Li, XY; Lin, YD; Liu, RY; Luo, XQ; Sun, X; Sun, XF; Wu, XD; Xu, HG | 1 |
| Fang, Q; Gong, B; Gong, X; Gu, R; Jin, J; Li, Y; Lin, D; Liu, B; Liu, K; Liu, X; Liu, Y; Ma, Y; Mi, Y; Qiu, S; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhang, J; Zhou, C | 1 |
| Algarra, L; Ayala, R; Bergua, JM; Calasanz, MJ; Falantes, JF; Gil, C; Herrera, P; Labrador, J; Lavilla, E; Lopez, JL; Martinez, P; Martínez-Cuadrón, D; Martinez-Lopez, J; Montesinos, P; Paiva, B; Prosper, F; Ramos, F; Salamero, O; San-Miguel, JF; Sanz, MÁ; Sayas, MJ; Serrano, J; Simoes, C; Tormo, M; Vidriales, MB; Villar, S; Vives, S | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Borthakur, G; Kantarjian, H | 1 |
| Jaramillo, S; Schlenk, RF | 1 |
| Alonzo, T; Beckman, A; Berman, JN; Brodersen, L; Chisholm, K; Druley, T; Gamis, A; Gerbing, R; Heerema-McKenney, A; Hijiya, N; Hirsch, B; Hitzler, J; Kolb, EA; Loken, M; O'Brien, M; Raimondi, S; Schore, R; Taub, J; Tong, S; Viola, S; Wang, YC | 1 |
| Borkhardt, A; Dilloo, D; Escherich, G; Faber, J; Feuchtinger, T; Horstmann, MA; Imschweiler, T; Jorch, N; Pekrun, A; Schmid, I; Schramm, F; Spohn, M; Zimmermann, M; Zur Stadt, U | 1 |
| Balsat, M; Barraco, F; Baudouin, A; Cadassou, O; Ducastelle, S; Elhamri, M; Fossard, G; Gutrin, J; Hayette, S; Heiblig, M; Labussière, H; Larcher, MV; Plesa, A; Roumier, C; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Kang, Q; Londoño-Joshi, A; Malek, SN; Parkin, B; Rhim, AD; Tewari, M | 1 |
| Chen, SN; Fu, ZZ; Li, WY; Qiu, HY; Sun, AN; Wang, Y; Wu, DP | 1 |
| Berdel, WE; Bormann, E; Braess, J; Büchner, T; Flasshove, M; Görlich, D; Haferlach, C; Hecht, A; Hiddemann, W; Hofmann, WK; Horst, HA; Kreuzer, KA; Krug, U; Lengfelder, E; Lindemann, HW; Nowak, D; Sauerland, C; Schiel, X; Schliemann, C; Schneider, S; Schnittger, S; Spiekermann, K; Wörmann, B | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Burnett, AK; Cahalin, P; Cavenagh, JD; Couzens, S; Dillon, R; Freeman, SD; Gilkes, A; Grimwade, D; Hills, RK; Jones, G; Khan, N; Khwaja, A; Nielsen, OJ; Russell, NH; Thomas, I; Upton, L; Virgo, P | 1 |
| Coltoff, A; Houldsworth, J; Keyzner, A; Mascarenhas, J; Renteria, AS | 1 |
| Bhatnagar, N; Greenough, A; James, B; Norton, A; O'Marcaigh, AS; Roberts, I; Tunstall, O; Vyas, P; Watts, T; Wright, M | 1 |
| Creutzig, U; de Haas, V; Flasinski, M; Klusmann, JH; Reinhardt, D; Reinhardt, K; Scheibke, K; van der Velden, VHJ; Verwer, F; von Neuhoff, C; Zimmermann, M; Zwaan, CM | 1 |
| Edwin, NC; Kahl, B | 1 |
| Bae, S; Costa, LJ; Erba, HP; Jamy, O; Papadantonakis, N | 1 |
| Ali, OM; Baer, MR; Duong, VH; El Chaer, F; Emadi, A; Griffiths, EA; Koka, R; Law, JY; Lee, ST; Sausville, EA; Singh, ZN; Wong, J; Yared, JA | 1 |
| Chung, HJ; Han, SH; Hur, M; Kim, H; Lee, MH; Moon, HW; Yoon, S; Yun, YM | 1 |
| Arora, N; Gogoi, M; Islam, R; Krishnan, S; Kumar Mishra, D; Parihar, M; Roy, P; Saha, D; Saha, V | 1 |
| Cai, X; Chen, X; Li, C; Liang, Y; Wang, H; Xia, Z | 1 |
| Ballerini, F; Cagnetta, A; Cea, M; Clavio, M; Colombo, N; Gobbi, M; Guolo, F; Lemoli, RM; Marcolin, R; Miglino, M; Minetto, P; Todiere, A | 1 |
| Boyerinas, B; Hyjek, EM; Price, TT; Sipkins, DA; Yesilkanal, AE; Zafrir, M | 1 |
| Bartram, CR; Koehler, R | 1 |
| Eckert, C; Henze, G; v Stackelberg, A | 1 |
| Karawajew, L; Ludwig, WD; Möricke, A; Ratei, R; Schabath, R; Schrappe, M; Zimmermann, M | 1 |
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Go, A; Guo, R; Parthasarathy, M; Rodriguez, T; Smith, S; Sobol, U; Stiff, P; Vimr, R | 1 |
| Bowman, WP; Campana, D; Coustan-Smith, E; Dahl, G; Inaba, H; O'Hear, C; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shi, L; Taub, JW | 1 |
| Advani, AS; Appelbaum, FR; Becker, M; Coutre, S; Elkins, S; McDonough, S; Mims, M; O'Donnell, M; Othus, M; Radich, J; Wood, B | 1 |
| Bentzen, H; Bogsrud, TV; Brown, Pde N; Delabie, J; Ehinger, M; Elonen, E; Fagerli, UM; Frederiksen, H; Geisler, CH; Grønbæk, K; Hansen, PB; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kostova-Aherdan, K; Laurell, A; Lauritzsen, GF; Lehmann, AK; Loft, A; Nilsson-Ehle, H; Pedersen, LB; Ralfkiaer, E; Räty, R; Schildt, J; Sundstrom, C | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Chen, J; Chen, L; Gao, L; Gong, S; Hu, X; Liu, M; Lu, S; Ni, X; Qiu, H; Song, X; Wang, J; Wang, L; Xu, S; Xu, X; Yang, J; Zhang, W | 1 |
| Goulden, N; Hancock, J; Hough, R; Mitchell, C; Moorman, AV; Rowntree, C; Vora, A; Wade, R | 1 |
| Castaigne, S; Cayuela, JM; Chevret, S; Dombret, H; Hayette, S; Lambert, J; Nibourel, O; Pautas, C; Preudhomme, C; Renneville, A; Rousselot, P; Terré, C | 1 |
| Caballero, D; Corradini, P; Dreger, P; Dreyling, M; Geisler, C; Ghielmini, M; Hermine, O; Kimby, E; Le Gouill, S; Robinson, S; Rule, S; Vitolo, U | 1 |
| Koh, K | 1 |
| Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A | 1 |
| Basso, G; Beqiri, V; Bisio, V; Buldini, B; Fagioli, F; Locatelli, F; Manara, E; Masetti, R; Pession, A; Pigazzi, M; Putti, MC; Rizzari, C; Rondelli, R; Tregnago, C | 1 |
| Grimwade, D; Kayser, S; Schlenk, RF; Walter, RB; Yosuico, VE | 1 |
| Brunet, S; Castro, N; Chillón, MC; Díez-Campelo, M; González, M; Herrera, P; López, J; Mateo, M; Mateos, MV; Montesinos, P; Ocio, EM; Olave, MT; Oriol, A; Pérez-Simón, JA; Prieto-Conde, MI; San Miguel, JF; Sanz, MÁ; Vidriales, MB | 1 |
| Ashton, JM; Balys, M; Becker, MW; Calvi, LM; Eberhardt, A; Mendler, JH; Myers, JR; Sivagnanalingam, U; Wang, N | 1 |
| Burger, JA; Champlin, R; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Garris, R; Huang, X; Jabbour, E; Kantarjian, HM; Kebriaei, P; McCue, DA; O'Brien, SM; Ravandi, F; Rytting, ME; Thomas, DM; Verstovsek, S; Wierda, WG | 1 |
| Cortes, JE; Garcia-Manero, G; Garris, R; Issa, GC; Jabbour, E; Kantarjian, H; Luthra, R; O'Brien, SM; Patel, K; Ravandi, F; Sasaki, K; Short, NJ; Thomas, D | 1 |
| DeAngelo, DJ; Ravandi, F; Stein, EM | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Cortes, J; Daver, N; DiNardo, C; Estrov, Z; Garcia-Manero, G; Huang, X; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Pierce, S; Ravandi, F; Wang, S; Wang, X | 1 |
| Borthakur, G; Champlin, RE; Cortes, JE; Daver, N; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Kebriaei, P; Khouri, I; Konopleva, M; O'Brien, SM; Pierce, S; Qiao, W; Ravandi, F; Sasaki, K; Short, NJ; Thomas, D; Yin, CC | 1 |
| Barr, PM; Bernstein, SH; Blum, KA; Cashen, AF; Chen, RW; Cheson, BD; Constine, L; Faham, M; Fenske, TS; Fisher, RI; Forman, SJ; Friedberg, JW; Kahl, BS; Kahwash, S; Leblanc, M; Leonard, JP; Li, H; Phillips, T; Rimsza, LM; Shea, TC; Smith, SM; Wilkins, J | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Amadori, S; Ammatuna, E; Arcese, W; Buccisano, F; Cerretti, R; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Lo Coco, F; Maurillo, L; Neri, B; Ottaviani, L; Panetta, P; Quaresima, M; Rizzo, M; Sarlo, C; Spagnoli, A; Venditti, A; Venditti, D | 1 |
| Basso, G; Biondi, A; Fabbri, G; Locatelli, F; Paganin, M; Polato, K; Rizzari, C; Zecca, M | 1 |
| Asano, H; Hangaishi, A; Hosoi, M; Kurokawa, M; Takahashi, T; Yamamoto, G | 1 |
| Borthakur, G; Estey, EE | 1 |
| Airewele, G; Bowman, WP; Campana, D; Cao, X; Coustan-Smith, E; Dahl, G; Degar, B; Downing, JR; Inaba, H; Lacayo, NJ; Leung, W; Meshinchi, S; Onciu, M; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Taub, J | 1 |
| Kantarjian, H; O'Brien, S | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Hamamoto, K; Hanada, R; Horibe, K; Imaizumi, M; Kigasawa, H; Kobayashi, R; Kudo, K; Morimoto, A; Nakayama, H; Tabuchi, K; Tawa, A; Tsuchida, M; Tsuchiya, S; Tsukimoto, I; Yabe, H | 1 |
| Apibal, S; Banklau, C; Hongeng, S; Jindadamrongwech, S; Paisooksantivatana, K; Pakakasama, S; Sawangpanich, R | 1 |
| Blach, L; Borowitz, MJ; Bowman, WP; Camitta, BM; Carroll, AJ; Carroll, WL; Devidas, M; Hunger, SP; Larsen, EL; Linda, SB; Pullen, DJ; Shuster, J; Willman, CL; Winick, N | 1 |
| Boudova, L; Briere, J; Bron, D; Chevalier, C; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Jack, A; Mounier, N; Rosenwald, A; Schmitz, N; Soulier, J; Sundstrom, C; Thieblemont, C; Trougouboff, P; Voelker, HU; Ysebaert, L | 1 |
| Stone, RM | 1 |
| Luger, SM | 1 |
| Abdelhamid, E; Berthon, C; Castaigne, S; Gardin, C; Gruson, B; Helevaut, N; Nibourel, O; Preudhomme, C; Renneville, A; Rousselot, P; Soua, Z | 1 |
| Ayari, S; Chevallier, P; Delaunay, J; Dumas, PY; Eveillard, M; Guillaume, T; Leguay, T; Lippert, E; Mohty, M; Pigneux, A; Robillard, N | 1 |
| Attarbaschi, A; Beier, R; Lauten, M; Meissner, B; Möricke, A; Niemeyer, C; Niggli, F; Odenwald, E; Riehm, H; Schrappe, M; Stanulla, M; Zimmermann, M | 1 |
| Kaspers, GJ | 1 |
| Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M | 1 |
| Béné, MC; Berthon, C; Blanchet, O; Boissel, N; Bulabois, CE; Cayuela, JM; Chevret, S; Cornillet, P; Delabesse, E; Delaunay, J; Dombret, H; Guardiola, P; Ifrah, N; Jourdan, E; Lioure, B; Luquet, I; Pautas, C; Pigneux, A; Preudhomme, C; Raffoux, E; Recher, C; Renneville, A; Terré, C; Thomas, X; Vey, N | 1 |
| Goulden, N; Hancock, J; Hough, R; Mitchell, C; Richards, S; Rowntree, C; Vora, A; Wade, R | 1 |
| Algara, P; Díaz, MA; Madero, L; Martínez, P; Ramírez, M; Tutor, O | 1 |
| Bilhou-Nabera, C; Blaise, D; Boiron, JM; Boucheix, C; Bourhis, JH; Buzyn, A; Cayuela, JM; Charrin, C; Delannoy, A; Dombret, H; Espérou, H; Fegueux, N; Fenaux, P; Fière, D; Gabert, J; Lhéritier, V; MacIntyre, E; Rigal-Huguet, F; Thomas, X; Vernant, JP | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Ravindranath, Y | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Barbui, T; Benedetti, F; Capria, S; Carlo-Stella, C; Corradini, P; Cortelazzo, S; Di Nicola, M; Gianni, AM; Magni, M; Martelli, M; Parvis, G; Patti, C; Pilotti, S; Rambaldi, A; Tarella, C | 1 |
| Akiyama, T; Fujimi, A; Hirayama, Y; Kato, J; Kawano, Y; Kobune, M; Kohda, K; Kuroda, H; Matsunaga, T; Miyake, K; Niitsu, Y; Sakamaki, S; Sato, T; Takemoto, N; Takimoto, R; Tanaka, I | 1 |
| Ueda, T | 1 |
| Haferlach, T; Hiddemann, W; Kern, W; Schnittger, S; Schoch, C; Voskova, D | 1 |
| Camera, A; Cimino, G; Cuneo, A; Foà, R; Izzo, B; Mancini, M; Mandelli, F; Martinelli, G; Mecucci, C; Pane, F; Picardi, M; Quintarelli, C; Rotoli, B; Saglio, G; Salvatore, F; Specchia, G; Vitale, A | 1 |
| Cortes, J; Dewald, GW; Kantarjian, HM; Litzow, ML; Mauro, MJ; Talpaz, M; Tefferi, A | 1 |
| Borkhardt, A; Bruch, J; Fuchs, U; Metzler, M; Perez, AV; Wilda, M; Woessmann, W | 1 |
| Karp, JE; Smith, BD | 1 |
| Fonatsch, C; Gaiger, A; Jäger, U; Kainz, B; Schwarzinger, I; Sperr, WR | 1 |
| Hayashi, Y; Kanazawa, T; Morikawa, A; Ogawa, C; Taketani, T; Taki, T | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Marcucci, G | 1 |
| Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F | 1 |
| Li, JY; Qian, SX; Qiu, HR; Shen, RL; Wu, YJ; Zhang, JF; Zhang, SJ; Zhou, HF | 1 |
| Emerenciano, M; Mata, JF; Mori, BO; Pombo-de-Oliveira, MS; Queiroz, RP; Scrideli, CA; Tone, LG | 1 |
| Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M | 1 |
| Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Brand, R; Dreger, P; Michallet, M | 1 |
| Fukai, F; Kodama, H; Matsunaga, T; Miura, S; Nagaya, T; Nakane, Y; Niitsu, Y; Owaki, T; Takayama, T; Takimoto, R; Tanaka, M | 1 |
| Kurahashi, S; Narimatsu, H; Sugimoto, T; Sugiura, I; Yamamoto, F | 1 |
| D'Onofrio, G; Di Mario, A; Etuk, B; Leone, G; Salutari, P; Sica, S | 1 |
| Caron, PC; Finn, RD; Jurcic, JG; Larson, SM; Maslak, P; Miller, WH; Scheinberg, DA; Warrell, RP; Yao, TJ | 1 |
| Brunetti, I; Bruzzone, M; Conte, PF; Fioretti, P; Gadducci, A; Ragni, N | 1 |
| Bradstock, K; Brisco, J; Enno, A; Hughes, E; McCaul, K; Morley, AA; Neoh, SH; Sykes, PJ; Szer, J | 1 |
| Babini, L; Barbieri, E; Battista, G; Bendandi, M; Canini, R; Fanti, S; Frezza, G; Gherlinzoni, F; Gozzetti, A; Merla, E; Monetti, N; Pisi, P; Rimondi, MR; Tura, S; Zinzani, PL; Zompatori, M | 1 |
| Cremer, F; Döhner, H; Goldschmidt, H; Haas, R; Hunstein, W; Moos, M; Schmohl, D; Schulz, R; Sucker, C | 1 |
| Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M | 1 |
| Chomienne, C; Degos, L; Fenaux, P | 1 |
| Goldberg, SL; Klumpp, TR; Mangan, KF; Ming, PL; Mullaney, MT; Rao, PN; Redei, I | 1 |
| Dibenedetto, SP; Lo Nigro, L; Mayer, SP; Rovera, G; Schilirò, G | 1 |
| Avvisati, G; Capria, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petti, MC; Vignetti, M | 1 |
| Asano, S; Inoue, T; Nagayama, H; Nishiwaki, K; Okamoto, S; Oshima, Y; Takahashi, S; Tani, K; Tojo, A | 1 |
| Burke, PJ; Gore, SD; Weng, LJ | 1 |
| Izumi, Y; Sawada, H; Serino, Y; Wake, A; Yamasaki, Y | 1 |
| Benner, A; Haas, R; Martin, S; Moos, M; Schulz, R | 1 |
| Algara, P; Díaz, MA; Madero, L; Martínez, P; Tutor-Ureta, O | 1 |
| Andreeff, M; Champlin, RC; Dong, J; Estey, EH; Estrov, Z; Jiang, S; Konopleva, M; Kornblau, SM; Okcu, MF; Reed, JC; Sanchez-Williams, G; Snell, VE; Xie, Z; Zhang, X; Zhao, S | 1 |
| Fasching, K; Gadner, H; Panzer, S; Panzer-Grümayer, ER; Schneider, M | 1 |
| Braess, J; Büchner, T; Haferlach, T; Hiddemann, W; Kern, W; Schoch, C; Unterhalt, M; Wörmann, B | 1 |
| Boros, B; Egyed, M; Földi, J; Páldi-Haris, P; Rumi, G | 1 |
| Bash, R; Hosler, GA; Scheuermann, RH | 1 |
| Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL | 1 |
| Behm, FG; Boyett, JM; Campana, D; Coustan-Smith, E; Hancock, ML; Pui, CH; Raimondi, SC; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sancho, J; Sandlund, JT | 1 |
| Abgrall, JF; Colombat, P; Cornillet, P; Deconinck, E; Delain, M; Gardembas, M; Kootz, C; Milpied, N; Tourani, JM | 1 |
| Bloomfield, CD; Caligiuri, MA; Marcucci, G | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Powell, BL | 1 |
| Armitage, JO; Bierman, PJ; Chan, WC; Inwards, D; Kessinger, A; Loh, K; Lynch, JC; Nichols, C; Rifkin, R; Sharp, G; Vose, JM; Weisenburger, DD | 1 |
19 review(s) available for cytarabine and Minimal Disease, Residual
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Core binding factor acute myelogenous leukemia-2021 treatment algorithm.
Topics: Algorithms; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human; Core Binding Factors; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Neoplasm, Residual; Translocation, Genetic | 2021 |
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Analysis; Transplantation, Homologous | 2021 |
Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bone Marrow; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease Management; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Risk Assessment; RUNX1 Translocation Partner 1 Protein; Sequence Analysis, DNA | 2018 |
Evolving treatment strategies in mantle cell lymphoma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Neoplasm, Residual; Rituximab; Stem Cell Transplantation | 2018 |
[Current treatment of pediatric acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Topic; Cytarabine; Dexamethasone; Drug Discovery; Humans; Imatinib Mesylate; Induction Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines | 2014 |
Minimal residual disease-directed therapy in acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein | 2015 |
Therapy of acute myelogenous leukemia in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Clinical Trials as Topic; Combined Modality Therapy; Core Binding Factors; Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 2010 |
Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Child; Cytarabine; Disease Management; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2011 |
Is a nadir bone marrow required and, if so, what to do with residual disease?
Topics: Anthracyclines; Antineoplastic Agents; Biopsy; Bone Marrow; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Practice Guidelines as Topic; Prognosis; Remission Induction; Retrospective Studies; Sensitivity and Specificity; Survival Rate; United States | 2011 |
Pediatric acute myeloid leukemia.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Complementary Therapies; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Neoplasm, Residual; Secondary Prevention; Survival Rate; Therapies, Investigational; Transplantation, Homologous; Treatment Outcome | 2012 |
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Biomarkers, Tumor; Child; Chromosome Aberrations; Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid; Mitoxantrone; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2003 |
[Recent progress in diagnosis of and therapy for patients with leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Targeting; Genes, Wilms Tumor; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Pharmacogenetics; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Therapeutic Equivalency; Tretinoin | 2004 |
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Treatment Outcome | 2005 |
Autologous stem cell transplantation for chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Neoplasm, Residual; Neoplasms, Second Primary; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2007 |
Acute promyelocytic leukemia: biology and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Translocation, Genetic; Tretinoin | 1997 |
Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Topics: Animals; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor alpha Subunits; Cytarabine; Diagnosis, Differential; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Analysis; Transcription Factor AP-2; Transcription Factors; Translocation, Genetic; Treatment Outcome | 2000 |
Acute progranulocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Prognosis; Salvage Therapy; Survival Analysis; Tretinoin | 2001 |
41 trial(s) available for cytarabine and Minimal Disease, Residual
| Article | Year |
|---|---|
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate | 2021 |
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Finland; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prospective Studies; Remission Induction; Thioguanine | 2022 |
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Treatment Outcome; Vincristine; Young Adult | 2021 |
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Remission Induction | 2021 |
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Topics: Antimetabolites, Antineoplastic; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplasm, Residual; Prognosis; Treatment Outcome | 2021 |
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acut
Topics: Acute Disease; Antineoplastic Agents; Child; Clofarabine; Cytarabine; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2022 |
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm, Residual; Treatment Outcome | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.
Topics: Adult; Aged; Alleles; Anthracyclines; Bone Marrow; Cytarabine; Exome; Female; Hematopoiesis; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Phenotype; Prognosis; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Consolidation Chemotherapy; Cytarabine; Cytogenetic Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Topics: Cytarabine; Disease Progression; Down Syndrome; Historically Controlled Study; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Leukemoid Reaction; Neoplasm, Residual; Survival Analysis | 2018 |
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Retrospective Studies; Risk Factors; Time Factors; Vidarabine | 2018 |
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Genetic Markers; Humans; Mercaptopurine; Methotrexate; Neoplasm, Residual; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Vincristine | 2013 |
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Infant; Leukemia, Biphenotypic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Analysis; Vincristine | 2013 |
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Survival Analysis; Treatment Outcome | 2013 |
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Topics: Adenine Nucleotides; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Cytarabine; Febrile Neutropenia; Female; Heart Arrest; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Young Adult | 2014 |
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radioimmunotherapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Methotrexate; Mucositis; Neoplasm, Residual; Pancreatitis; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Risk Assessment; Stomatitis; Survival Rate; Vincristine | 2014 |
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; RNA, Messenger; Treatment Outcome; WT1 Proteins | 2014 |
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis | 2015 |
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Idarubicin; Indoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Neoplasm, Residual; Panobinostat; Prognosis; Recurrence; Treatment Outcome | 2015 |
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Treatment Outcome; Vincristine; Young Adult | 2015 |
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2017 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Mercaptopurine; Methotrexate; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prednisone; Prognosis; Prospective Studies; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2008 |
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Remission Induction; Survival Rate; Young Adult | 2010 |
Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Cytarabine; Epidemiologic Methods; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Neoplasm, Residual; Neutropenia; Prognosis; Recurrence; Treatment Outcome; Tretinoin | 2011 |
Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Alleles; Antigens, CD19; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gene Frequency; Genotype; Humans; Infant; Leukocyte Common Antigens; Male; Mucositis; Neoplasm Staging; Neoplasm, Residual; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thrombocytopenia; Treatment Outcome | 2010 |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Thioguanine; Treatment Outcome; Vincristine | 2011 |
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infant; Lymphocyte Count; Male; Mercaptopurine; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine | 2012 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation | 2013 |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Core Binding Factors; Cytarabine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Genes, Neoplasm; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Prognosis; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Humans; Infant; Ireland; Male; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Treatment Outcome; United Kingdom; Vincristine | 2013 |
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vincristine | 2005 |
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Transplantation, Homologous | 2007 |
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2007 |
Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Italy; Neoplasm, Residual; Ovarian Neoplasms; Pilot Projects; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction | 1994 |
Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Mercaptopurine; Methotrexate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Survival Analysis; Treatment Outcome; Vincristine | 1996 |
Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gallium Radioisotopes; Hodgkin Disease; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Mediastinal Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prednisone; Radioimmunodetection; Radiotherapy; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vincristine | 1996 |
Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Genes, bcl-2; Genes, Immunoglobulin; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Sepsis; Survival Analysis; Thrombocytopenia; Translocation, Genetic; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Proportional Hazards Models; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2002 |
86 other study(ies) available for cytarabine and Minimal Disease, Residual
| Article | Year |
|---|---|
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis | 2022 |
Hitzler J, Alonzo T, Gerbing R, et al. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021;138(23):2337-2346.
Topics: Cytarabine; Humans; Neoplasm, Residual; Prognosis | 2022 |
Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity.
Topics: Animals; Cytarabine; Disease Models, Animal; Disease Progression; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasm, Residual | 2022 |
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies | 2023 |
[Acute myeloid leukemia harboring NUP98::DDX10].
Topics: Cytarabine; DEAD-box RNA Helicases; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Nuclear Pore Complex Proteins; Prognosis; Recurrence | 2022 |
Prolonged Survival Using Outpatient Palliative Chemotherapy in Two Children With Refractory Acute Myelogenous Leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Outpatients; Quality of Life | 2023 |
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Rate; Vincristine | 2020 |
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Infant, Newborn; Lymphoma, B-Cell; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Prednisone; Retrospective Studies; Vincristine | 2020 |
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Topics: Adolescent; Adult; Aged; Alleles; Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Progression-Free Survival; Recurrence; Risk Assessment; Young Adult | 2020 |
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; SARS-CoV-2 | 2020 |
Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chlorambucil; Cytarabine; Female; Follow-Up Studies; Humans; India; Male; Mitoxantrone; Neoplasm, Residual; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Survival Rate | 2020 |
Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Germinal Center; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous | 2021 |
Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Neoplasm Recurrence, Local; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2021 |
Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; RUNX1 Translocation Partner 1 Protein; Young Adult | 2021 |
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Topics: Adult; Aged; Biomarkers, Tumor; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Prognosis; Retrospective Studies; Young Adult | 2021 |
Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2018 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.
Topics: Antimetabolites, Antineoplastic; Blood Cell Count; Cell Transformation, Neoplastic; Critical Illness; Cytarabine; DNA Mutational Analysis; Down Syndrome; Exchange Transfusion, Whole Blood; Female; Fetal Diseases; GATA1 Transcription Factor; Humans; Leukapheresis; Leukemoid Reaction; Liver Diseases; Mutation; Neoplasm, Residual; Pregnancy; Prenatal Diagnosis; Prognosis; Recurrence; Risk Factors | 2018 |
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.
Topics: Adult; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Combined Modality Therapy; Cytarabine; Dasatinib; Daunorubicin; Drug Substitution; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm, Residual; Neoplastic Stem Cells; Remission Induction | 2019 |
Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Translocation, Genetic | 2019 |
Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; India; Infant; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate | 2019 |
Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Risk; Time Factors; Treatment Outcome; Vincristine | 2019 |
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Salvage Therapy; Survival Rate | 2019 |
Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy.
Topics: Adult; Animals; Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Blast Crisis; Bone Marrow; Cell Adhesion; Child; Child, Preschool; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasm, Residual; Osteoblasts; Osteopontin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Transplantation, Heterologous; Tumor Microenvironment | 2013 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Europe; Hematopoietic Stem Cell Transplantation; Humans; Mercaptopurine; Methotrexate; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Retreatment; Survival Rate; Vincristine | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Chromosome Aberrations; Consolidation Chemotherapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prognosis; RUNX1 Translocation Partner 1 Protein; Young Adult | 2014 |
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Consensus Development Conferences as Topic; Cytarabine; Europe; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Remission Induction; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2015 |
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Monitoring; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Survival Analysis; Transcription Factors; Translocation, Genetic | 2015 |
Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
Topics: Animals; Anthracyclines; Bone Marrow; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Cytarabine; Cytogenetic Analysis; DNA Mutational Analysis; Exome; Humans; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplasm, Residual; Xenograft Model Antitumor Assays | 2015 |
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Infant; Male; Methotrexate; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Vincristine | 2016 |
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Remission Induction | 2016 |
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Topics: Adult; Aged; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction | 2017 |
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Cytodiagnosis; Disease-Free Survival; Doxorubicin; Female; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Treatment Outcome; Vincristine | 2017 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2008 |
Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Monocytic, Acute; Male; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Remission Induction | 2010 |
Questions regarding frontline therapy of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Retreatment | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Germinal Center; Humans; Ifosfamide; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphoma, Large B-Cell, Diffuse; Male; Microarray Analysis; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Proteins; Neoplasm, Residual; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rituximab; Salvage Therapy | 2011 |
Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Tandem Repeat Sequences; WT1 Proteins | 2012 |
Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Risk Factors; Rituximab; Salvage Therapy; Survival Rate; Vincristine; Young Adult | 2012 |
Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Deletion; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Genes, p16; Humans; Infant; Life Tables; Loss of Heterozygosity; Male; Mercaptopurine; Methotrexate; Microsatellite Repeats; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2002 |
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Patient Selection; Ploidies; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Rituximab; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.
Topics: Animals; Antibodies; Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance, Neoplasm; Fibronectins; Humans; Integrin alpha4beta1; Integrin alpha5beta1; Leukemia; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm, Residual; Phosphatidylinositol 3-Kinases; Predictive Value of Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stromal Cells; Survival Rate; Time Factors; Tumor Cells, Cultured | 2003 |
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Prognosis; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thioguanine | 2004 |
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA-Binding Proteins; Etoposide; GTPase-Activating Proteins; Histone-Lysine N-Methyltransferase; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogenes; RNA, Messenger; Transcription Factors | 2005 |
Curing acute myelogenous leukemia: still a major challenge.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Risk Factors; Survival Analysis | 2005 |
Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Tretinoin | 2005 |
TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Cytarabine; Etoposide; Exons; Humans; Idarubicin; Infant; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA-Binding Protein FUS; Translocation, Genetic; Treatment Outcome | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
Core binding factor acute myeloid leukemia.
Topics: Acute Disease; Core Binding Factors; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Neoplasm, Residual; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Treatment Outcome | 2006 |
[Bulky lymphadenopathy in acute myeloid leukemia with inv (16) (p13q22): a case report].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Lymphatic Diseases; Male; Neoplasm, Residual; Prognosis | 2006 |
Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Case-Control Studies; Child; Child, Preschool; Cytarabine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Humans; Infant; Male; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Messenger; Time Factors | 2006 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2006 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Adhesion; Cell Line, Tumor; Cytarabine; Drug Resistance; Drug Therapy, Combination; Fibronectins; Humans; Integrin beta1; Leukemia, Myeloid, Acute; Mice; Neoplasm, Residual; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2008 |
Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lenograstim; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Tissue and Organ Harvesting | 2008 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Humans; Idarubicin; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Tretinoin; Vincristine | 1994 |
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Neutropenia; Nuclear Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Transcription Factors; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 1995 |
Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Topics: Acute Disease; Base Sequence; Burkitt Lymphoma; Cytarabine; Dose-Response Relationship, Immunologic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Molecular Sequence Data; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Transcription, Genetic | 1995 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prednisolone; Recombinant Fusion Proteins; RNA, Messenger; Translocation, Genetic | 1997 |
Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Chromosome Deletion; Chromosomes, Human, Pair 20; Clone Cells; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Hematopoietic Cell Growth Factors; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm, Residual; Neoplasms, Second Primary; Neoplastic Stem Cells; Prednisone; Procarbazine; Radiotherapy; Recurrence; Transplantation, Autologous; Vinblastine; Vincristine | 1997 |
Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blotting, Southern; Bone Marrow; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; DNA, Neoplasm; Evaluation Studies as Topic; Female; Fluorometry; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Immunophenotyping; Infant; Italy; Leucovorin; Leukemia-Lymphoma, Adult T-Cell; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Stem Cells; Nucleic Acid Hybridization; Polymerase Chain Reaction; Prednisone; Prognosis; Prospective Studies; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Vincristine | 1997 |
Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Tretinoin | 1997 |
Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia.
Topics: Adult; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm, Residual; Recombinant Proteins | 1998 |
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Middle Aged; Neoplasm, Residual; Remission Induction; Tumor Stem Cell Assay | 1998 |
Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Humans; Leukemia, Myeloid; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Recombinant Fusion Proteins; Remission Induction; RNA-Directed DNA Polymerase; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic | 1998 |
The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Recurrence; Remission Induction; Translocation, Genetic | 1998 |
[The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; DNA Primers; Genes, T-Cell Receptor delta; Humans; Mercaptopurine; Methotrexate; Molecular Sequence Data; Neoplasm, Residual; Polymerase Chain Reaction; Prednisone; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Vincristine | 1999 |
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cytarabine; Down-Regulation; Flow Cytometry; Gene Expression; Genes, bcl-2; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Neoplasm, Residual; Phosphorylation; Phosphoserine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Survival Rate; Tretinoin; Tumor Cells, Cultured | 1999 |
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Gene Rearrangement; Humans; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Risk; Time Factors; Treatment Outcome; Vincristine | 2000 |
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm, Residual; Prognosis; Prospective Studies; Recurrence; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Interferons; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Remission Induction; Tretinoin | 2000 |
Kinetics of early therapeutic response as measured by quantitative PCR predicts survival in a murine xenograft model of human T cell acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Calibration; Cell Cycle; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Doxorubicin; Drug Evaluation; Etoposide; Female; Flow Cytometry; Humans; Leukemia-Lymphoma, Adult T-Cell; Methotrexate; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Reference Standards; Risk Assessment; Specific Pathogen-Free Organisms; Survival Analysis; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 2000 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Mediastinal Neoplasms; Melphalan; Middle Aged; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Etoposide; Female; Flow Cytometry; Humans; Hydrocortisone; Immunophenotyping; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Cells, Circulating; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Remission Induction; Treatment Outcome; Vincristine | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |